Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03559192 · ClinicalTrials.gov registry record · Phase 2
A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression
A Phase 2 study of Depressive Disorder, Major, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 181
- Enrollment target
- 20
- Study locations
NCT03559192 is a Phase 2 study of Depressive Disorder, Major that has completed, run by Janssen Research & Development. The registered enrollment target is 181 participants, below the 239-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT03559192, a Phase 2 study of Depressive Disorder, Major, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 181 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of JNJ-67953964 compared to placebo when administered as adjunctive treatment in participants with Major Depressive Disorder (MDD) partially responsive to selective serotonin reuptake inhibitor/ serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) treatment in terms of reduction of symptoms of depression, as assessed by the change from baseline on the Montgomery Asberg Depression Rating Scale (MADRS) in non-responders during the placebo lead-in period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG JNJ-67953964
Study Locations (20)
California
- Behavioral Research Specialists LLC - Glendale
- NRC Research Institute - Orange
- Artemis Institute for Clinical Research - Riverside
- Artemis Institute for Clinical Research - San Marcos
- Pacific Clinical Research Medical Group - Upland
Florida
- Innova Clinical Trials - Miami
- Galiz Research - Miami Springs
- APG Research LLC - Orlando
- Olympian Clinical Research - Tampa
- Meridien Research - Tampa
Illinois
- Chicago Research Center - Chicago
- Psychiatric Medicine Associates LLC - Skokie
New York
- Integrative Clinical Trials LLC - Brooklyn
- Richmond Behavioural Associates - Staten Island
Arizona
- Noble Clinical Research - Tucson
Arkansas
- Preferred Research Partners - Little Rock
Georgia
- Atlanta Behavioral Research, LLC - Atlanta
Louisiana
- Lake Charles Clinical Trials - Lake Charles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2018-07-16 |
| Est. Completion | 2020-05-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03559192
The ClinicalTrials.gov registry entry for NCT03559192 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (24% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03559192 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT03559192 about?
NCT03559192 is a clinical study titled "A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression". The purpose of this study is to evaluate the efficacy of JNJ-67953964 compared to placebo when administered as adjunctive treatment in participants with Major Depressive Disorder (MDD) partially responsive to selective serotonin reuptake inhibitor/ serotonin-norepinephrine reuptake inhibitor (SSRI/S...
What is the current status of trial NCT03559192?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 2018-07-16. Estimated completion is 2020-05-06.
What conditions does trial NCT03559192 study?
This clinical trial studies the following conditions: Depressive Disorder, Major.
What interventions are being tested in trial NCT03559192?
The interventions under investigation include: Placebo (DRUG), JNJ-67953964 (DRUG).
Who is sponsoring clinical trial NCT03559192?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03559192 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
RECRUITING · Phase 2
-
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
RECRUITING · Phase 2
-
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
RECRUITING · Phase 2
-
Individualized Functional Connectivity Targeting in aiTBS for Depression
ACTIVE NOT RECRUITING · Phase 2
-
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.